Eppendorf initiates import ban against Nanosphere's Verigene and Verigene SP systems

NewsGuard 100/100 Score

Eppendorf has initiated an import ban for Nanosphere, Inc.'s Verigene(R) and Verigene(R) SP systems for infringement of European patent EP 1 179 180 B2, titled "Method for the identification and/or the quantification of a target compound". The import ban covers any and all imports of the respective products into any country of the European Union. Customs authorities are required to confiscate any violating products.

The patent covers Eppendorf's Silverquant(R) microarray technology, offered in Eppendorf's Silverquant scanner and Silverquant detection kit used e.g. for Eppendorf's own microarrays. The technology is also licensed to two companies for commercialization with their microarrays.

In addition, Eppendorf has successfully initiated an import ban for the Verigene(R) kits based on the German utility model DE 20023342U1, also covering Eppendorf's Silverquant products. This ban prohibits imports into Germany either from outside the EU or from within the EU.

"Considering Nanosphere's announcement of having received the CE mark for the Verigene(R) system, Eppendorf has taken these steps to prevent the introduction of these products that are not licensed to use our patented technology into the European Union", commented Sven Bulow, Managing Director of Eppendorf Biochip Systems GmbH.

In fiscal 2008, the company's sales revenues amounted to EUR 410 million with earnings before interest and taxes (EBIT) of EUR 71.9 million.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study to test novel psychedelic compound as potential treatment for alcohol use disorder